Evidence map›Paper›PMID 26811325›Full record

ArticleCancer discovery2016

Tumor Cell-Driven Extracellular Matrix Remodeling Drives Haptotaxis during Metastatic Progression.

Madeleine J Oudin, Oliver Jonas, Tatsiana Kosciuk, Liliane C Broye, Bruna C Guido, Jeff Wyckoff, Daisy Riquelme, John M Lamar, Sreeja B Asokan, Charlie Whittaker and 9 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer discovery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 126 papers.

0numbers the graph read from it
0cells of the map it votes in
126citing papers in PubMed
15.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

126 citing papers in PubMed, 213 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Haptotactic Motion of Multivalent Vesicles Along Ligand-Density Gradients.Langmuir : the ACS journal of surfaces and colloids · 2025
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

66 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

Madeleine J OudinDavid H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts.
Oliver JonasDavid H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts.
Tatsiana KosciukDavid H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts.
Liliane C BroyeDavid H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts.
Bruna C GuidoDavid H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts.
Jeff WyckoffDavid H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts.
Daisy RiquelmeDavid H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts.
John M LamarDavid H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts.
Sreeja B AsokanLineberger Comprehensive Cancer Center, UNC Chapel Hill, Chapel Hill, North Carolina.
Charlie WhittakerDavid H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts.
Duanduan MaDavid H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts.
Robert LangerDavid H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts.
Michael J CimaDavid H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts.
Kari B WisinskiDepartment of Medicine, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin.
Richard O HynesDavid H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts. Department of Biology, MIT, Cambridge, Massachusetts. Howard Hughes Medical Institute, Chevy Chase, Maryland.
Douglas A LauffenburgerDavid H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts. Department of Biological Engineering, MIT, Cambridge, Massachusetts.
Patricia J KeelyDepartment of Cell and Regenerative Biology, University of Wisconsin Madison, Madison, Wisconsin.
James E BearLineberger Comprehensive Cancer Center, UNC Chapel Hill, Chapel Hill, North Carolina. Howard Hughes Medical Institute, Chevy Chase, Maryland.
Frank B GertlerDavid H. Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts. Department of Biology, MIT, Cambridge, Massachusetts. fgertler@mit.edu.
Howard Hughes Medical Institute · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MATTHEW G. VANDER HEIDEN · 1985 to 2026
$93.9M
Tumor Cell Networks CenterU54CA112967 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LAUFFENBURGER, DOUGLAS A · 2004 to 2015
$26.2M
The Extracellular Matrix in Tumor Progression and MetastasisU54CA163109 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI HYNES, RICHARD O · 2011 to 2015
$3.7M
Dynamics of Gene and Isoform Regulation during EMT and tumor progressionU01CA184897 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BURGE, CHRISTOPHER B, GERTLER, FRANK B · 2014 to 2018
$3.4M
Mechanisms Of Cell Migration On 3D Aligned MatricesR01CA142833 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI FRIEDL, ANDREAS, HAHN, KLAUS M. · 2010 to 2020
$3.4M
Multiscale Modeling of ECM-tumor interactions in Breast CancerU01CA143069 · NCI · VANDERBILT UNIVERSITY · PI JIANG, YI, KEELY, PATRICIA J · 2011 to 2015
$2.3M
Biophysical Regulation of Breast DifferentiationR01CA114462 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI KEELY, PATRICIA J · 2010 to 2014
$1.5M
Mechanisms of mesenchymal chemotaxisR01GM110155 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BEAR, JAMES E, HAUGH, JASON M. · 2014 to 2017
$1.4M
NCI NIH HHS P30 CA014051NCI NIH HHS P30 CA016086NCI NIH HHS R01 CA114462NCI NIH HHS R01 CA142833NCI NIH HHS U01 CA143069NCI NIH HHS U01 CA184897NCI NIH HHS U54 CA112967NCI NIH HHS U54 CA163109NIGMS NIH HHS R01 GM110155
6 · The paper itself

Abstract

unlabelledFibronectin (FN) is a major component of the tumor microenvironment, but its role in promoting metastasis is incompletely understood. Here, we show that FN gradients elicit directional movement of breast cancer cells, in vitro and in vivo Haptotaxis on FN gradients requires direct interaction between α5β1 integrin and MENA, an actin regulator, and involves increases in focal complex signaling and tumor cell-mediated extracellular matrix (ECM) remodeling. Compared with MENA, higher levels of the prometastatic MENA(INV) isoform associate with α5, which enables 3-D haptotaxis of tumor cells toward the high FN concentrations typically present in perivascular space and in the periphery of breast tumor tissue. MENA(INV) and FN levels were correlated in two breast cancer cohorts, and high levels of MENA(INV) were significantly associated with increased tumor recurrence as well as decreased patient survival. Our results identify a novel tumor cell-intrinsic mechanism that promotes metastasis through ECM remodeling and ECM-guided directional migration. SIGNIFICANCE: Here, we provide new insight into how tumor cell:ECM interactions generate signals and structures that promote directed tumor cell migration, a critical component of metastasis. Our results identify a tumor cell-intrinsic mechanism driven by the actin regulatory protein MENA that promotes ECM remodeling and haptotaxis along FN gradients. Cancer Discov; 6(5); 516-31. ©2016 AACR.See related commentary by Santiago-Medina and Yang, p. 474This article is highlighted in the In This Issue feature, p. 461.

Indexed as

Cell MovementActinsAnimalsBreast NeoplasmsCell Line, TumorCollagenDisease Models, AnimalDisease ProgressionExtracellular MatrixFemaleFibronectinsGene ExpressionHeterograftsHumansIntegrin alpha5beta1Kaplan-Meier EstimateActinsCollagenEnah protein, humanFibronectinsIntegrin alpha5beta1Microfilament Proteins

Identifiers

PMID26811325
PMCPMC4854754
OpenAlexW2271528576

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.